← Oncology Approval Tracker

FDA DECISION ·

Reblozyl

luspatercept-aamt · Celgene / Bristol Myers Squibb

FDA approvalNew or expanded indicationMyelodysplastic syndromes
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For anemia in adults with very low- to intermediate-risk MDS who have not received an erythropoiesis-stimulating agent and may require regular red blood cell transfusions.

LAMPGEN ANALYSIS

Why it matters

The action broadened anemia treatment to patients without prior ESA exposure.

What research teams should watch

Document risk category, ESA history and transfusion baseline before assessing the response to therapy.

PRIMARY RECORDS

Sources